Viking Therapeutics, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Viking Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2017 was $73.14K.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2017-12-31 | $73.14K 10-K · filed 2018-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |